Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS
Content archived on 2024-06-18

Preclinical proof of concept of AF243 potency to prevent and/or treat sensorineural hearing loss

Objective

Approximately 10% of the global population (40% of people over 65), suffers hearing difficulties. The socio-economic impact is deep, since in children, early hearing impairment (HI) affects language learning, and in adults, acquired HI impairs social integration. The sense of hearing depends upon the integrity of the sensory epithelia in the inner ear. HI occurs when this tissue is disrupted, that is when the sensory hair cells (HC) die and the spiral ganglion neurons (SGN) subsequently degenerate and die. To date, there is no potent curative or preventive solution for HI, the clinical options are based on the use of prostheses such as cochlear implants. Studies are being conducted to develop alternative treatments combining both preventive and reparative strategies. Since HC and SGN are of the same developmental origin, transcription and growth factors that modulate early development of the inner ear have been under the scope. These studies gave rise to two main therapeutic hypotheses, the use of exogenous stem cell with induction of their differentiation to HC and/or SGN, or the proliferation/transdifferentiation of cells supporting HC in the inner ear. Up to now, problems of cell death and control of the cell differentiation have slowed down the emergence of new therapies.
To address this problem, AFHELO projects plans to evaluate potency of AF243, a small molecule which is a strong inducer of cell differentiation with interesting potencial on carcino-embryonic cells differentiation and neuron survival, and on an in vivo model of chemo-induced deafness, used for cochlear implant testing.
The strategy is to optimize AF243 development by first extending the therapeutic applications to two major types of HI (noise-induced and age related/presbycusis) and second by completing the preclinical studies (pharmacology, mechanism of action, ADME, safety) supporting the clinical evaluation of AF243 for prevention and/or treatment of sensorineural HI.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.

You need to log in or register to use this function

Programme(s)

Multi-annual funding programmes that define the EU’s priorities for research and innovation.

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

FP7-HEALTH-2012-INNOVATION-2
See other projects for this call

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

CP-FP - Small or medium-scale focused research project

Coordinator

AFFICHEM SA
EU contribution
€ 1 444 971,00
Address
RUE SAINT JOSEPH 9
31400 TOULOUSE
France

See on map

Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

No data

Participants (2)

My booklet 0 0